Aradigm to Present at Merriman Curhan Ford’s 4th Annual Investor Summit on September 17

Aradigm Corporation (OTCBB:ARDM) today announced that President and Chief Executive Officer Igor Gonda, Ph.D. will present at the Merriman Curhan Ford 4th Annual Investor Summit on Monday, September 17, 2007, at 2:15 p.m. Pacific time.

This event will be held at the Mark Hopkins InterContinental Hotel in San Francisco.

More information about the conference can be found at: www.merrimanco.com

Interested parties can access a live audio webcast and slide presentation at www.aradigm.com. An archived presentation will be available on the Company’s Web site for 14 days.

About Aradigm

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. Current activities include partnered and self-initiated development programs addressing the treatment of cystic fibrosis, bronchiectasis, pulmonary hypertension, inhalation anthrax infections and smoking cessation.

In addition, Aradigm’s AERx® insulin Diabetes Management System (iDMS), which has been licensed to Novo Nordisk for development and commercialization in return for royalties, is in Phase 3 testing for Type 1 and Type 2 diabetes. Under the agreements with Novo Nordisk, Novo Nordisk is responsible for all further clinical, manufacturing and commercial development, while Aradigm and Novo Nordisk continue to cooperate and share in technology development, as well as intellectual property development and defense. More information about Aradigm can be found at www.aradigm.com.

Aradigm, AERx, and AERx Essence are registered trademarks and the Aradigm Logo is a trademark of Aradigm Corporation.

SOURCE: Aradigm